Retrospective study comparing allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed/refractory acute lymphoblastic Leukemia
Latest Information Update: 23 Dec 2018
At a glance
- Drugs Anti-CD19 chimeric-antigen-receptor-T-cell-therapy-Yake-Biotechnology (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
Most Recent Events
- 23 Dec 2018 New trial record
- 05 Dec 2018 Results published in the Bone Marrow Transplantation